在瑞士向宫颈癌筛查未参加者提供HPV自检的成本效果评价
该研究基于决策树与马尔可夫队列模拟,比较三种筛查策略与不筛查在瑞士未参加宫颈癌筛查女性中的终生效果与成本。向未参加者提供HPV自检可预防90%宫颈癌和94%宫颈癌相关死亡,每获得1个质量调整生命年的增量成本效果比为11138至12413美元,低于现行细胞学筛查的22488美元。作者认为HPV自检是成本效果更优的方案。
要点
- 向未参加者提供HPV自检可预防90%宫颈癌和94%宫颈癌相关死亡
- 现行细胞学筛查可减少83%宫颈癌病例和88%宫颈癌相关死亡
- HPV自检联合阴道镜或Pap分流的ICER为每QALY 11138至12413美元,低于Pap/HPV的22488美元
核心结论
- 在瑞士向未参加宫颈癌筛查的女性提供HPV自检是成本效果良好的策略,与宫颈癌病例和相关死亡的减少相关。
- HPV自检比现行细胞学筛查更具成本效果。
研究设计与样本
- 采用一年周期递归决策树模拟终生自然HPV感染史,并用马尔可夫队列模拟评估模型预期结局。
- 比较三种筛查策略与不筛查:HPV自检联合阴道镜分流(Self-HPV/colpo)、HPV自检联合Pap细胞学分流(Self-HPV/PAP)、细胞学筛查联合HPV分流(PAP/HPV)。
- 对模型关键参数进行敏感性分析以检验结果的稳健性。
主要发现
- 向未参加者提供HPV自检可预防研究人群中90%的宫颈癌和94%的宫颈癌相关死亡。
- 现行细胞学筛查方案可在人群终生内减少83%的宫颈癌病例和88%的宫颈癌相关死亡。
- 与不筛查相比,每挽救一个质量调整生命年(QALY)的增量成本效果比(ICER):Self-HPV/colpo为12413美元,Self-HPV/Pap为11138美元,PAP/HPV为22488美元。
关键数值与推荐
- Self-HPV/colpo策略的ICER为每QALY 12413美元。
- Self-HPV/Pap策略的ICER为每QALY 11138美元。
- PAP/HPV策略的ICER为每QALY 22488美元。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: About 30% of women who are eligible for cervical cancer (CC) screening remain un-screened or under-screened in Switzerland. HPV testing on self-collected vaginal samples (Self-HPV) has shown to be more sensitive than cytology while also reaching non-attendees. The objective of this study was to explore the cost-effectiveness of offering Self-HPV to non-attendees in Switzerland. METHODS: A recursive decision-tree with one-year cycles was used to model the life-long natural HPV history. Markov cohort simulations were used to assess the expected outcomes from the model. The outcomes of three strategies were compared with the absence of screening: Self-HPV and triage with colposcopy (Self-HPV/colpo), Self-HPV and triage with Pap cytology (Self-HPV/PAP), cytological screening and triage with HPV (PAP/HPV). Sensitivity analyses for the key parameters of the model were conducted to check the robustness of findings. RESULTS: Offering a Self-HPV screening to non-attendees could prevent 90% of CC and 94% of CC-related deaths in the study population. The current cytology-based program could reduce by 83% the number of CC cases and by 88% the number of CC-related deaths over the population's lifetime. Compared to the absence of screening, incremental cost-effectiveness ratios (ICER) were estimated to be, per saved Quality Adjusted Life Year (QALY), 12413US$ for the strategy Self-HPV/colpo, 11138US$ for the strategy Self-HPV/Pap and 22488US$ for the strategy PAP/HPV. CONCLUSIONS: Offering Self-HPV as a CC screening strategy to non-attendees in Switzerland is a cost-effective solution that is associated with a reduction of CC cases and related deaths. Self-HPV is more cost-effective than the currently used cytology-based screening.
引用
- Vassilakos P, Poncet A, Catarino R, et al. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland. Gynecol Oncol. 2019. PMID: 30718124. doi:10.1016/j.ygyno.2019.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。